Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsChugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
Overview of Elevidys for Intravenous Infusion
Yoko Sano, Elevidys Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
Duchenne Muscular Dystrophy (DMD): Disease and Treatment, Clinical Framework for Gene Therapy, Appropriate Use, and Clinical Positioning
Hirofumi Komaki, M.D., Ph.D., Director, Translational Medical Center National Center Hospital, National Center of Neurology and Psychiatry
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2025(Integrated Report)
Past Annual Report
What's New
-
Transcript (including Q&A) for Chugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Chugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Annual Report 2025
-
Events & Presentations has been updated with the Date of Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Script (including Q&A) for Conference on FY2026.12 Q1 Financial Results
-
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
-
Avastin Receives Approval for Additional Indication as the World’s First Treatment for Neurofibromatosis Type 2
-
Anti-CD20 Monoclonal Antibody Rituxan® Approved for Adult-onset Frequently Relapsing or Steroid-dependent Nephrotic Syndrome
-
Tecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancer
-
Chugai Receives “The Imperial Invention Prize,” the Highest Honor of the FY2026 National Commendation for Invention — Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research —
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
